Zydus Lifesciences has secured final approval from the US health regulator for its generic Leuprolide Acetate injection. This medication is used for palliative treatment of advanced prostate cancer. The company's facility in Ahmedabad will manufacture the injections. The drug had significant annual sales in the US market. This development marks a key milestone for Zydus Lifesciences in the oncology segment.